JP2024546098A - ラベキシモド化合物 - Google Patents

ラベキシモド化合物 Download PDF

Info

Publication number
JP2024546098A
JP2024546098A JP2024534019A JP2024534019A JP2024546098A JP 2024546098 A JP2024546098 A JP 2024546098A JP 2024534019 A JP2024534019 A JP 2024534019A JP 2024534019 A JP2024534019 A JP 2024534019A JP 2024546098 A JP2024546098 A JP 2024546098A
Authority
JP
Japan
Prior art keywords
compound
salt
rheumatoid arthritis
compound according
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546098A5 (https=
Inventor
ブラウン，ウィリアム ダルビー
ピンクステレン，ローレンス アドリアヌス ヘンドリクス ヴァン
エリバート スティーンダム，リエンク
ニッベ，ジョナサン
イングリッド ベルト―ルド，マリン
Original Assignee
シクソン エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シクソン エービー filed Critical シクソン エービー
Publication of JP2024546098A publication Critical patent/JP2024546098A/ja
Publication of JP2024546098A5 publication Critical patent/JP2024546098A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fire-Extinguishing Compositions (AREA)
JP2024534019A 2021-12-09 2022-12-08 ラベキシモド化合物 Pending JP2024546098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21213418 2021-12-09
EP21213418.3 2021-12-09
PCT/EP2022/085060 WO2023104998A1 (en) 2021-12-09 2022-12-08 Rabeximod compounds

Publications (2)

Publication Number Publication Date
JP2024546098A true JP2024546098A (ja) 2024-12-17
JP2024546098A5 JP2024546098A5 (https=) 2025-12-25

Family

ID=78827545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534019A Pending JP2024546098A (ja) 2021-12-09 2022-12-08 ラベキシモド化合物

Country Status (8)

Country Link
US (1) US11643415B1 (https=)
EP (1) EP4444720A1 (https=)
JP (1) JP2024546098A (https=)
KR (1) KR20240115849A (https=)
CN (1) CN118647618A (https=)
AU (1) AU2022407139A1 (https=)
CA (1) CA3239544A1 (https=)
WO (1) WO2023104998A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230022880A (ko) * 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE527639C2 (sv) 2004-06-17 2006-05-02 Oxypharma Ab Alkylsubstituerade indolokinoxaliner
EA201500942A1 (ru) * 2013-03-15 2016-03-31 Виронова Херпес Аб ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
KR20230022880A (ko) 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형

Also Published As

Publication number Publication date
CA3239544A1 (en) 2023-06-15
AU2022407139A1 (en) 2024-05-23
EP4444720A1 (en) 2024-10-16
CN118647618A (zh) 2024-09-13
KR20240115849A (ko) 2024-07-26
WO2023104998A1 (en) 2023-06-15
US11643415B1 (en) 2023-05-09

Similar Documents

Publication Publication Date Title
US8124603B2 (en) In vivo studies of crystalline forms of meloxicam
US9452157B2 (en) Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereof
JP2014530805A (ja) アジルサルタンの結晶形並びにその製造及び使用
JP2011506374A (ja) テノホビルジソプロキシルの固形物
AU2014351028B2 (en) Solid forms of Ivacaftor and processes for the preparation thereof
TW202012362A (zh) 稠合三環γ-胺基酸衍生物之組合物及其製備方法
JP2024546098A (ja) ラベキシモド化合物
CA2962724C (en) Salt of dicarboxylic acid compound
CN111971272A (zh) 柳氮磺吡啶盐组合物及其使用方法
US8344145B2 (en) Salts of 2-substituted quinolines
US11306062B2 (en) Forms of fedratinib dihydrochloride
US20200095255A1 (en) Crystalline Forms of Ponatinib Hydrochloride
WO2008108630A1 (en) Polymorphic forms of efavirenz
AU2004232495B2 (en) 4-(4-trans-hydroxycyclohexyl)amino-2-phenyl-7h-pyrrolo [2, 3d]pyrimidine hydrogen mesylate and its polymorphic forms
AU2010277947B2 (en) R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl- 6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial
WO2000058310A1 (en) Zolpidem salts
KR20190090729A (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
CN102770416A (zh) 美他沙酮共晶体
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
AU2024319768A1 (en) Crystalline form h1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hemihydrate
JP2018515477A (ja) 免疫調節薬の新規な結晶形
WO2025032190A1 (en) Crystalline form a1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hcl
WO2024009977A1 (ja) ５Ｈ－ピロロ［２，３－ｄ］ピリミジン－６（７Ｈ）－オン及びその塩体の結晶
WO2025227089A1 (en) Solid state forms of (2r,3s)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-n-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide
WO2025156044A1 (en) Crystalline forms of ozanimod hydrochloride

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251205